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Abstract
The importance of the patients point of view on their health status is widely recognised. Patient-
reported outcomes is a broad term encompassing a large variety of different health data reported
by patients, as symptoms, functional status, Quality of Life and Health-Related Quality of Life.
Measurements of Health-Related Quality of Life have been developed during many years of
researches, and a lot of validated questionnaires exist. However, few attempts have been made to
standardise the evaluation of instruments characteristics, no recommendations are made about
interpretation on Health-Related Quality of Life results, especially regarding the clinical significance
of a change leading a therapeutic approach. Moreover, the true value of Health-Related Quality of
Life evaluations in clinical trials has not yet been completely defined. An important step towards a
more structured and frequent use of Patient-Reported Outcomes in drug development is
represented by the FDA Guidance, issued on February 2006.
In our paper we aim to report some considerations on this Guidance. Our comments focus
especially on the characteristics of instruments to use, the Minimal Important Difference, and the
methods to calculate it. Furthermore, we present the advantages and opportunities of using the
Patient-Reported Outcomes in drug development, as seen by a pharmaceutical company. The
Patient-Reported Outcomes can provide additional data to make a drug more competitive than
others of the same pharmacological class, and a well demonstrated positive impact on the patient'
health status and daily life might allow a higher price and/or the inclusion in a reimbursement list.
Applying extensively the FDA Guidance in the next trials could lead to a wider culture of subjective
measurement, and to a greater consideration for the patient's opinions on his/her care. Moreover,
prescribing doctors and payers could benefit from subjective information to better define the value
of drugs.
Introduction
The importance of the patients point of view on their
health status and healthcare is widely recognized [1].
Patient-reported outcomes (PROs) provide the patient's
perspective on health outcome endpoint data [2-4]. PROs
can play an important role in the development of new
drugs, especially those aimed to treat medical conditions
in which only subjective data allow to evaluate the treat-
ment effect [1].
PROs is a broad term encompassing a large variety of dif-
ferent health data reported by patients. PROs as symp-
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toms, functional status, treatment adherence, satisfaction
with care represent useful data to corroborate the clinical
data (efficacy and safety), helping clinicians to better
define the drug profile.
Furthermore, inside the PROs we meet a couple of impor-
tant concepts, sometimes considered as synonymous.
These concepts are the Quality of Life (QoL) and the
Health-Related Quality of Life (HRQoL). The QoL is a
complex, abstract, multidimensional concept defining an
individual satisfaction with life in domains he/she consid-
ers important. The HRQoL reflects an attempt to restrict
the complex concept of QoL to those aspects of life specif-
ically related to the individual health, and potentially
modified by healthcare [5]. HRQoL data are not always
foreseeable and necessarily correlated with the severity of
the disease as perceived by healthcare professionals.
Moreover, the symptoms/HRQoL correlation could be
weak (for example, no abdominal pain during a medical
examination but a poor patient's HRQoL, because of the
impairment of the patient personal life and leisure, his/
her need to take drugs, dietary restrictions etc.).
HRQoL measurements has been developed during many
years of research (proven by thousand of published
papers), and a lot of validated questionnaires exist, both
generic and disease specific. However, the following
points need to be considered: 1) although the operational
application of concepts and their validation process have
been well codified, few attempts have been made to stand-
ardise the evaluation of instruments characteristics; 2)
usually, the criteria regard intrinsic characteristics of the
questionnaires (reliability, validity etc.), while no recom-
mendations are made about interpretation on HRQoL
results, especially regarding the clinical significance of a
change in HRQoL leading a therapeutic approach; 3)
despite some scientific society have created working
groups to debate the role of HRQoL in clinical research,
the true value of HRQoL evaluations in clinical trials has
not yet been completely defined [5,8,9].
The contribution given by the PROs measurement could
be important in the process of drug approval by regulatory
authorities. Furthermore, on the regulatory side some fac-
tors limit the use of PROs, and HRQoL in particular. The
main limiting factors are: 1) the abuse of the term HRQoL
in clinical trials. This term is used also when other PROs
are measured (symptoms, drug side effects etc.). 2) The
poor quality of the majority of clinical trials having the
HRQoL as primary endpoints. 3) The role and the signifi-
cance of HRQoL as efficacy, tolerance, utility endpoint
[10,11]
These points and the reasonable scepticism of regulatory
authorities to officially acknowledge some subjective cri-
terion whose clinical meaning remains difficult, have lim-
ited the use of PROs in the drugs approval process. At the
moment, it could be quite difficult to make acceptable
HRQoL to regulatory authorities as a primary endpoint,
since some regulators consider it as a less rigorous second-
ary endpoint.
An important step towards a more structured and frequent
use of PROs in drug development has been done by FDA.
On February 2006 the FDA issued the Guidance, that
describes how it evaluates PROs used as effectiveness end-
points in clinical trials.
Specific comments to the Guidance
The Guidance is potentially very useful for all concerned
in planning, designing and carrying out clinical trials for
regulatory purposes. It provides information on how to
choose a PRO instrument. Although the Guidance is clear
enough and take into consideration a lot of important
topics on PRO instruments (their development, assess-
ment of measurement properties, modification of existing
instruments), study design and data analysis, it could be
improved to make it more applicable to NDA trials and
facilitate univocal interpretation of results by experts and
regulators.
The reading of the FDA Guidance firstly led to some gen-
eral considerations and comments on the PROs. We aim
to briefly report these considerations.
PROs is an "umbrella term". It contains physical function-
ing, psychological well-being, global health perception,
treatment satisfaction and other subjective outcomes.
Therefore, PRO is not interchangeable with QoL or
HRQoL.
QoL has never been approved in a labelling claim because
of its vagueness. On the contrary, HRQoL could be a pos-
sible endpoint. This should be very clear when measuring
PROs.
The inclusion of PROs assessment in clinical trials should
have a good scientific rationale. The risk of an indiscrimi-
nate measuring of PROs is producing useless and con-
founding data.
The conceptual framework of a single-item symptom
measure is not so complex as a multiple frameworks to
define HRQoL. Multiple domains questionnaires usually
are required in early phases of drug development, when
researchers investigate the activity of a new compound
more than its efficacy. In this phase the need to focus the
attention on the domains more affected by the disease (or
by the disease management) makes useful a multi-
domains questionnaire. In later phases, when needs andHealth and Quality of Life Outcomes 2006, 4:85 http://www.hqlo.com/content/4/1/85
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expectations of pts are well known, a single or few
domains questionnaire helps to a better interpretation of
changes.
HRQoL measurements is more useful in chronic diseases
(for example rheumatoid arthritis) than in life-threaten-
ing disease (cancer). In life-threatening diseases the only
acceptable main aim of the therapy is a longer survival. A
better HRQoL and a worsened survival make that drug
probably not approved by regulatory authorities.
PROs should not replace safety reporting, as safety is an
important concern of regulatory authorities.
Researchers aiming to measure HRQoL must use existing,
validated instruments. The development of new question-
naires should be discouraged, but the standardisation of
questionnaires should be encouraged. In particular, the
development of a questionnaire for a certain study should
be definitely avoided. The sponsor of the study has to pro-
vide evidence of validity of the selected instrument (for
example, a list of published papers on the development,
validation and use in clinical trials of the questionnaire).
When an existing questionnaire is used in a new popula-
tion (elderly rather than adults) or in a different context
(on outpatients basis rather than inpatients), a re-valida-
tion is required.
The instrument used to measure a PRO should have a doc-
umented evidence of responsiveness/sensitivity to
changes in health status. In fact, small differences in PRO
scores, although statistically significant, are often ques-
tioned with regard to their clinical importance. It is not
always clear what is meant by clinically importance, i.e.,
discernible to the patient, significant enough for a clini-
cian to change an intervention, or significant from a pop-
ulation perspective. Hence if a PRO cannot detect a
meaningful change in health status, its use may be risky,
because clinically meaningful effects may be undetected
[2,6].
Demonstrating responsiveness is necessary to determine
the Minimal Important Difference (MID), where MID rep-
resents the smallest change perceived by the patient as an
advantage, or that could lead to a change of treatment [6].
The MID can be calculated using a number of anchor-
based or distribution-based methods. Distribution-based
approaches are the effect size (ES), the standardised
response mean and the standard error of measurement
(SEM). Anchor-based methods assess which changes on
the measurement instrument correspond with a minimal
important change defined on a anchor. Distribution-
based methods do not provide a good indication of the
importance of the observed change. Anchor-based
approaches do not take measurement precision into
account. Sometimes results obtained using these different
approaches are similar [12].
At the moment, there is not a clear agreement on the rec-
ommended, best practice approach for determining the
MID [7]. The application of multiple methods, even if
imperfect, to the same datasets could tend to give similar
results and this should clarify the relationship between
these methods and give a better estimate of the MID. Fur-
thermore, some Authors report that for assessing the MID
anchor-based methods are preferred, as they include a def-
inition of what is minimally important [12].
These concepts should be more stressed in the Guidance.
The MID may vary by context, and different MID could be
valid for different studies where PROs instruments are
used. MID varies according different factors, such as the
underlying disease, the characteristics of the population,
the healthcare scenario, and so on. For these reasons, we
cannot have a unique MID for a PRO instrument, good for
different diseases and patients [7]. It is necessary that
responsiveness and MID be well documented in order to
use PROs in labelling claims.
The patient satisfaction is a PRO, but it could be greatly
influenced by factors such as, for example, the personal
relationship between the patient and the nurse/doctor.
This relationship can satisfy/dissatisfy the patient, and
represents an aspect related to the (variable) healthcare
structure/organization. For this reason we believe that the
patient satisfaction should be considered as a less impor-
tant indicator than HRQoL.
The users of the Guidance should appreciate more details
for sample size determination and handling missing data,
especially for the questionnaire development. Another
topic to be detailed is concerned with the proxy measures.
Furthermore, we are aware that the heterogeneity of clini-
cal settings, diseases and drugs makes very difficult to any-
body (including FDA) to prepare a technical
documentation applicable to any context.
The point of view of a pharmaceutical company
Certainly the drug developers are interested in a better def-
inition of the value of their drugs using PROs data. The
pharmaceutical industry has been the principal driving
force behind the expansion in the number and type of
HRQoL instruments available to clinician and researchers
[13].
Industry sees some advantages in PRO measurements.
Infact, PROs can provide additional data for inclusion ofHealth and Quality of Life Outcomes 2006, 4:85 http://www.hqlo.com/content/4/1/85
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a drug in a formulary, making that drug more competitive
than others of the same pharmacological class. Further-
more, an effective and well tolerated drug with a demon-
strated positive impact on the patient' health status and
daily life might allow to negotiate a higher price (where
the price of drugs is negotiated between pharmaceutical
companies and regulatory authorities) and/or the inclu-
sion in a reimbursement list.
Subjective data collection has to be regulated by clear
rules, agreed by all parts involved in the development and
approval of drugs. The Guidance is a positive and modern
attempt to provide a document helping the use of subjec-
tive data to support labelling claims. It stimulates phar-
maceutical companies to use a shared and accepted
methodology to provide data, although an alternative
approach is considered possible. This means longer time
to prepare and carry out a clinical trial, and more
expenses. On the other side, the adherence to the Guid-
ance should reduce the risk of rejection of PROs data by
FDA.
Furthermore, the Guidance offers a good opportunity to
the pharmaceutical industry to discuss about methodol-
ogy with regulatory authorities, and to become a trustwor-
thy partner of regulatory agencies.
The development of a new questionnaire (if needed) or
their revision/updating is a complex, time consuming and
expensive activity. Usually a pharmaceutical company can
provide financial support and technical knowledge to
develop subjective questionnaires by itself or in partner-
ship with a scientific society and academic experts. Ade-
quate resources can allow tool developers to reach an
exhaustive set of data to demonstrate the validity and reli-
ability of questionnaires. A further important step should
be the publication of papers, allowing the developers to
insert the new tools in a compendium, where all con-
cerned researchers and regulators can find the instruments
and replicate experiences to confirm the validity of the
instruments.
Regulatory authorities might recognise that the develop-
ment of a new instrument allows clinicians to have a use-
ful instrument to administer to their patients. The
companies could waive the copyright in favour of all
researchers and clinicians, obtaining, on the other hand,
both an increase of robustness of the tool and, maybe, a
reward by regulators.
A wider use of PRO measurements allows clinicians/pay-
ers to become familiar with PROs, integrating these data
in their evaluation criteria to prescribe or reimburse a
drug.
Conclusion
In conclusion, it is well known that the correlation
between the patient and the physician evaluation of a cer-
tain symptom could be poor and not univocal. HRQoL
and other PROs provide important patient perspective on
disease and the treatment they receive. A subjective evalu-
ation provides clinically important information not cap-
tured by objective measures. This is particularly important
in chronic diseases, as rheumatoid arthritis or asthma,
where HRQoL data capture the overall benefit given by
the treatment.
Despite a very large number of published papers on
HRQoL, there is a certain scepticism on the value of
HRQoL and other PROs. It is likely that clinicians do not
use PROs because they are not routinely trained in the use
and interpretation of PRO instruments [1]. Usually, the
interpretation of the clinical significance of a change in
HRQoL is considered difficult; particularly difficult is the
translation of results into an overall clinical evaluation
leading to a change of the current therapy [14,15].
In order to overcome this scepticism, it is necessary to
highlight the scientific and statistical basis of these meas-
urements, and the usefulness of collecting these data.
Moreover, it shall be demonstrated the improvement of
patients management by clinicians thanks to the use of
PROs data.
The use of these data to support a labelling claim requires
the use of a rigorous methodology, based on valid and
reliable instruments, used when appropriate.
A parallel European Guidance has not yet been conceived
by EMEA, and this is not surprising considering the differ-
ences between the American and European healthcare and
regulatory structures. This is reflected in a different mar-
keting approval process, which is first centrally granted
(EMEA), and subsequently discussed at the national level
(reimbursement, price). Furthermore, EMEA prepared a
Reflection Paper (July 2005), a short and generic docu-
ment that discusses the place that HRQoL may have in
drug evaluation process, and gives some broad recom-
mendations.
The FDA guidance represents the first step in a hard, com-
plex track to reach the best evidence in questionnaire
development and the use of PRO to support labelling
claims.
Applying extensively the Guidance in the next trials could
lead to a wider culture of subjective measurement, and to
take into a greater consideration the patient's point of
view on his/her care. Moreover, a more detailed evalua-Publish with BioMed Central    and   every 
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tion of drugs is helpful for prescribing doctors and payers,
to allow them to better define the value of drugs.
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